Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $2.58B |
| Gross Profit (TTM) | $1.79B |
| EBITDA | $-10.18M |
| Operating Margin | -12.80% |
| Return on Equity | -32.00% |
| Return on Assets | -2.21% |
| Revenue/Share (TTM) | $11.29 |
| Book Value | $1.39 |
| Price-to-Book | 20.27 |
| Price-to-Sales (TTM) | 2.59 |
| EV/Revenue | 2.821 |
| EV/EBITDA | 205.86 |
| Quarterly Earnings Growth (YoY) | -17.40% |
| Quarterly Revenue Growth (YoY) | 38.20% |
| Shares Outstanding | $224.94M |
| Float | $212.46M |
| % Insiders | 5.46% |
| % Institutions | 71.49% |
Volatility is currently contracting
In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition from compound to brand name GLP-1s, and his vision to bring down the cost of healthcare.
Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices. In an interview with CNBC, he also said the company's sale of compounded GLP-1 drugs helped to bring prices for the treatments down.
RADNOR, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.
I'm maintaining my buy on Hims & Hers Health, and the reasoning has moved past the branded GLP-1 transition that drove my May upgrade. 2Q revenue grew 38% to $753.2 million and management raised the full-year outlook to $3.1–$3.3 billion, while gross margin fell six points sequentially to 64%. HIMS is now a distribution layer for branded weight-loss drugs, a business that buys revenue with margin, and the EBITDA guide shows the bill.
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
LOS ANGELES, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company's possible violations of the federal securities laws.
BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company's possible violations of federal securities laws.
RADNOR, Pa., Aug. 12, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HIMS and any ticker you trade — then tracks every position and per-strategy win rate.
